Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jason Gerberry
BofA
Jason Gerberry
Wall Street Analyst
★★☆☆☆
#2120
on 13Foresight · ranked by our own returns
49%
Success Rate
+3.6%
Average Return
41 of 83 calls profitable · -9.6% vs benchmark
📈 Across the calls we could measure, roughly 49% of Jason Gerberry's ratings turned a profit when each position was held for 2 year — averaging +3.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

169 Buy 50 Hold 20 Sell
Jason's Stock Coverage 59 ratings · 2026-07-12
Company Date Position Consensus Price Target 2-Yr Return
BMY
Bristol-Myers Squibb
Jul 10, 2026 BUY Buy
+2.3% avg upside
42 analysts
$66.00
14.72% Upside
+0.0%
RPRX
Royalty Pharma
Jul 10, 2026 BUY Strong Buy
-3.5% avg upside
15 analysts
+0.0%
AXSM
Axsome Therapeutics
Jul 10, 2026 BUY Strong Buy
-5.1% avg upside
28 analysts
+0.0%
UTHR
United Therapeutics
Jul 10, 2026 HOLD Strong Buy
-22.7% avg upside
26 analysts
$613.00
12.12% Upside
+0.0%
TEVA
Teva Pharmaceutical
Jul 10, 2026 BUY Buy
-10.8% avg upside
39 analysts
$40.00
21.49% Upside
+0.0%
PFE
Pfizer
Jul 10, 2026 HOLD Buy
+39.2% avg upside
45 analysts
$26.00
7.66% Upside
+0.0%
VTRS
Viatris
Jul 10, 2026 SELL Buy
+41.8% avg upside
21 analysts
$14.00
13.93% Downside
-0.0%
MRK
Merck & Company
Jul 10, 2026 BUY Strong Buy
+4.0% avg upside
43 analysts
$141.00
14.23% Upside
+0.0%
JNJ
Johnson & Johnson
Jul 10, 2026 HOLD Strong Buy
-14.0% avg upside
36 analysts
$263.00
2.29% Upside
+0.0%
JAZZ
Jazz Pharmaceuticals
Jul 10, 2026 BUY Strong Buy
-9.6% avg upside
35 analysts
·
LLY
Eli Lilly & Co
Jul 10, 2026 BUY Strong Buy
-13.6% avg upside
47 analysts
$1334.00
12.18% Upside
+0.0%
IONS
Ionis Pharmaceuticals
Jul 09, 2026 BUY Strong Buy
+37.8% avg upside
43 analysts
$90.00
54.58% Upside
-9.4%
TARS
Tarsus Pharmaceuticals
Jul 08, 2026 BUY Strong Buy
+31.8% avg upside
16 analysts
$89.00
53.06% Upside
-14.2%
AMPH
Amphastar Pharmaceuticals
Jun 29, 2026 SELL Hold
+38.8% avg upside
11 analysts
$20.00
6.80% Upside
+9.6%
LQDA
Liquidia Technologies
Jun 29, 2026 HOLD Strong Buy
-27.4% avg upside
15 analysts
$79.00
1.34% Upside
+3.7%
ALKS
Alkermes
Jun 29, 2026 SELL Strong Buy
-25.0% avg upside
34 analysts
$38.00
26.85% Downside
-3.5%
EXEL
Exelixis
Jun 22, 2026 SELL Buy
-25.7% avg upside
33 analysts
$41.00
27.49% Downside
-10.4%
ABBV
AbbVie
Jun 22, 2026 BUY Strong Buy
-6.7% avg upside
46 analysts
$234.00
5.67% Downside
+7.9%
OCS
Oculis Holding
Jun 01, 2026 BUY Strong Buy
+181.4% avg upside
11 analysts
$35.00
156.70% Upside
-6.1%
BMRN
BioMarin Pharmaceutical
May 29, 2026 BUY Strong Buy
+59.6% avg upside
52 analysts
$80.00
35.28% Upside
+3.2%
IMVT
Immunovant
May 21, 2026 BUY Strong Buy
-1.8% avg upside
24 analysts
$43.00
8.35% Upside
+20.2%
GUTS
Fractyl Health, Inc.
May 14, 2026 BUY Strong Buy
+480.3% avg upside
7 analysts
$2.00
152.26% Upside
-20.1%
LENZ
LENZ Therapeutics
May 12, 2026 BUY Buy
+322.4% avg upside
17 analysts
$31.00
454.56% Upside
-26.6%
MLYS
Mineralys Therapeutics, Inc.
May 07, 2026 BUY Strong Buy
+58.6% avg upside
12 analysts
-3.3%
PCVX
Vaxcyte
May 07, 2026 BUY Strong Buy
+73.3% avg upside
15 analysts
+14.0%
ARWR
Arrowhead Pharmaceuticals
Apr 20, 2026 BUY Strong Buy
-13.4% avg upside
26 analysts
$93.00
21.76% Upside
+10.3%
XENE
Xenon
Mar 09, 2026 BUY Strong Buy
-8.6% avg upside
28 analysts
$77.00
11.74% Upside
+1.0%
AMLX
Amylyx Pharmaceuticals Inc
Mar 03, 2026 BUY Strong Buy
+38.9% avg upside
14 analysts
$19.00
6.97% Upside
+26.7%
HRMY
Harmony Biosciences Holdings
Feb 24, 2026 SELL Strong Buy
+27.4% avg upside
13 analysts
$28.00
23.99% Downside
-35.7%
TSE:BHC
Bausch Health Companies
Feb 18, 2026 SELL Buy
+784.6% avg upside
29 analysts
$7.09
4.73% Upside
·
OGN
Organon
Feb 13, 2026 SELL Sell
+9.9% avg upside
9 analysts
-83.0%
PROK
ProKidney
Jan 12, 2026 SELL Buy
+275.0% avg upside
12 analysts
$1.00
43.23% Downside
+21.9%
CPRX
Catalyst Pharma
Dec 08, 2025 BUY Strong Buy
-17.6% avg upside
15 analysts
$35.00
11.28% Upside
+35.9%
BHVN
Biohaven Ltd.
Nov 10, 2025 HOLD Buy
+47.2% avg upside
25 analysts
$10.00
35.79% Downside
+99.6%
NL:LKFT
Galapagos
Nov 07, 2025 SELL Sell
+98.9% avg upside
16 analysts
·
RLAY
Relay Therapeutics
Nov 06, 2025 BUY Strong Buy
+0.3% avg upside
19 analysts
$15.00
24.98% Downside
+189.4%
LKFT
Lakefront Biotherapeutics
Nov 06, 2025 SELL Buy
+249.3% avg upside
24 analysts
$28.00
7.45% Downside
·
LYRA
Lyra Therapeutics
May 23, 2024 HOLD Hold
+4164.0% avg upside
7 analysts
-95.4%
CHRS
Coherus Biosciences
Oct 30, 2023 HOLD Buy
+715.2% avg upside
18 analysts
-43.5%
ALLO
Allogene Therapeutics
Sep 28, 2023 HOLD Strong Buy
+662.1% avg upside
28 analysts
-63.3%
TVRD
Tvardi Therapeutics
Aug 09, 2023 SELL Strong Buy
+452.6% avg upside
23 analysts
$3.50
6.65% Upside
+78.0%
KYNB
Kyntra Bio
Aug 08, 2023 SELL Buy
+318.6% avg upside
15 analysts
$2.00
73.71% Downside
+75.8%
BYSI
Beyondspring
Jan 05, 2023 SELL Hold
+459.9% avg upside
8 analysts
$1.00
30.61% Downside
+11.9%
FNCHQ
Finch Therapeutics Group
May 17, 2022 BUY Strong Buy
+133.8% avg upside
3 analysts
$11.00
4.26% Upside
·
VRCA
Verrica Pharmaceuticals
Jul 15, 2020 HOLD Strong Buy
+192.1% avg upside
8 analysts
$10.00
59.77% Upside
-59.5%
VYNE
VYNE Therapeutics
Mar 11, 2020 BUY Strong Buy
+2017.3% avg upside
9 analysts
$32.00
4918.90% Upside
-95.5%
ALNY
Alnylam Pharma
Nov 13, 2019 BUY Strong Buy
+16.0% avg upside
51 analysts
$110.00
63.14% Downside
+88.6%
NBRVF
Nabriva Therapeutics
Aug 20, 2019 BUY Strong Buy
+13374900.0% avg upside
9 analysts
$6.00
5999900.04% Upside
·
DE:MRK
Merck KGaA
Jun 28, 2019 SELL Buy
-2.8% avg upside
33 analysts
·
SPRO
Spero Therapeutics
Oct 16, 2018 SELL Buy
+553.0% avg upside
12 analysts
$9.00
328.51% Upside
-52.8%
ARDX
Ardelyx
Nov 20, 2016 BUY Strong Buy
+156.7% avg upside
21 analysts
$18.00
240.94% Upside
-81.6%
HRTX
Heron Therapeutics
Nov 15, 2016 BUY Strong Buy
+6453.1% avg upside
21 analysts
$34.00
8104.54% Upside
+36.9%
PCRX
Pacira Pharmaceuticals
Nov 02, 2016 HOLD Buy
+52.8% avg upside
21 analysts
$37.00
45.27% Upside
+50.9%
PRGO
Perrigo Company
Aug 10, 2016 HOLD Buy
+567.5% avg upside
20 analysts
$81.00
692.48% Upside
-17.4%
AMRX
Amneal Pharmaceuticals
Aug 09, 2016 HOLD Strong Buy
+1.1% avg upside
18 analysts
$24.00
41.08% Upside
+34.2%
NVO
Novo Nordisk
Aug 08, 2016 HOLD Buy
+134.5% avg upside
26 analysts
+5.4%
IRWD
Ironwood Pharma
Aug 05, 2016 HOLD Buy
+165.7% avg upside
23 analysts
$14.00
213.18% Upside
+43.3%
NBIX
Neurocrine
Jul 13, 2016 BUY Strong Buy
-1.8% avg upside
37 analysts
$70.00
60.48% Downside
+121.3%
CARM
Carisma Therapeutics
Jan 19, 2016 HOLD Buy
+53081.8% avg upside
11 analysts
·
🔒 54 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Jason Gerberry — Frequently Asked Questions
How accurate are Jason Gerberry's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Jason's ratings were profitable over a one-year hold, with an average return of +3.1% per rating, or -5.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jason ranked on 13Foresight?
Jason Gerberry is currently ranked #2120 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jason cover?
Jason most recently has ratings on BMY, RPRX, AXSM, UTHR, TEVA, PFE, VTRS, MRK, JNJ, JAZZ, LLY, IONS and 47 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.